Vanda Pharmaceuticals' Tradipitant Under FDA Review Extension
ByAinvest
Friday, Nov 28, 2025 11:27 am ET1min read
VNDA--
The US FDA has extended its re-review of Vanda Pharmaceuticals' tradipitant for motion sickness by a few days. Tradipitant is a medication under investigation for the treatment of motion sickness. The FDA initially placed a partial clinical hold on long-term studies of tradipitant in September 2022. The agency was supposed to complete its review by November 26, but due to the extension, the review will now be completed by December 2.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet